Table 1.
Patient characteristics (n=25)
| N (%) | |
| Age, median (range) | 70.4 (54–82) |
| Sex, male/female | 23/2 (92/8) |
| Smoking history | |
| Current smoker | 6 (24) |
| Former smoker | 18 (72) |
| Never smoked | 1 (4) |
| ECOG-PS | |
| 0 | 8 (32) |
| 1 | 14 (56) |
| 2 | 3 (12) |
| Histology | |
| Adenocarcinoma | 9 (36) |
| Squamous cell carcinoma | 11 (44) |
| Large cell carcinoma | 3 (12) |
| Pleomorphic carcinoma | 1 (4) |
| Not otherwise specified | 1 (4) |
| Stage | |
| III | 11 (44) |
| IV | 12 (48) |
| Recurrence | 2 (8) |
| Driver mutation | |
| EGFR | 1 (4) |
| ALK | 0 (0) |
| None | 24 (96) |
| Number of previous regimens | |
| 0 | 7 (28) |
| 1 | 11 (44) |
| 2 | 4 (16) |
| ≥3 | 3 (12) |
| PD-L1 expression, tumor proportion score | |
| <1% | 10 (40) |
| 1%–49% | 3 (12) |
| ≥50% | 12 (48) |
| Regimen, nivolumab/pembrolizumab | 10/15 (40/60) |
| Confirmed response | |
| CR | 1 (4) |
| PR | 7 (28) |
| SD | 8 (32) |
| PD | 9 (36) |
ALK, anaplastic lymphoma kinase; CR, complete response; ECOG-PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; PD, progressive disease; PR, partial response; SD, stable disease.